Concepedia
Statistics
Publications
67
Citations
3.6K
H-Index
38
Active since
1982
Affiliations
Novartis (Germany)(Current)
Novartis (Switzerland)
Charité - Universitätsmedizin Berlin
University of Münster
Christian-Albrechts-Universität zu Kiel
Matthias Bräutigam is an author at Novartis (Germany) specializing in dermatology, medicine, and pharmacotherapy.
Publications per year
1982–2017
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase
Marcus Maurer, Sabine Altrichter, Thomas Bieber et al. · Journal of Allergy and Clinical Immunology · 2011 · 357 citations · Full text
Life Sciences, Immunology, Pharmacotherapy +10
Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study
Michael J. Meurer, Regina Fölster‐Holst, Gottfried Wozel et al. · Dermatology · 2002 · 220 citations · Full text
Medicine, Dermatology, Pharmacotherapy +17
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis
Jens‐Michael Jensen, Stephan Pfeiffer, Magdalena Witt et al. · Journal of Allergy and Clinical Immunology · 2009 · 165 citations
Medicine, Dermatology, Immunology +16
Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection
Matthias Bräutigam, Siegfried Nolting, R.E. Schopf et al. · BMJ · 1995 · 144 citations · Full text
Health Professions, Dermatology, Pharmacotherapy +16
Effect of omalizumab on angioedema in H <sub>1</sub> ‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ <scp>ACT</scp> , a randomized controlled trial
Petra Staubach, Martin Metz, Nadine Chapman‐Rothe et al. · Allergy · 2016 · 128 citations
Life Sciences, Pharmacology, Pharmacotherapy +13
1–5 of 67